Aclaris Therapeutics (ACRS) News Today $1.84 +0.02 (+1.10%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$1.84 +0.00 (+0.27%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $8.71 Consensus Price Target from AnalystsAugust 29 at 2:19 AM | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Buy" from BrokeragesAugust 28 at 3:10 AM | marketbeat.comAclaris Therapeutics to Participate in Two September Healthcare ConferencesAugust 27 at 8:00 AM | globenewswire.comAclaris Therapeutics Inc (ACRS) - Investing.comAugust 24, 2025 | investing.comAclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138August 18, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Privia Health Group (PRVA), Aclaris Therapeutics (ACRS)August 14, 2025 | theglobeandmail.comAclaris Therapeutics (NASDAQ:ACRS) Issues Quarterly Earnings ResultsAugust 10, 2025 | marketbeat.comEarnings Beat: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsAugust 10, 2025 | finance.yahoo.comAclaris Therapeutics Reports Q2 Loss, Highlights Progress in Immuno-Dermatology PipelineAugust 9, 2025 | msn.comAclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | globenewswire.comWedbush Has Pessimistic Outlook of ACRS FY2026 EarningsAugust 2, 2025 | marketbeat.comAclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis TrialAugust 1, 2025 | msn.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Buy" from BrokeragesAugust 1, 2025 | marketbeat.comAclaris Therapeutics (ACRS) Expected to Announce Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comAclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific OfficerJuly 30, 2025 | msn.comDecheng Capital LLC Raises Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)July 30, 2025 | marketbeat.comAclaris Therapeutics stock soars after positive Phase 2a trial resultsJuly 29, 2025 | investing.comAclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary EndpointsJuly 29, 2025 | globenewswire.comAclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Leadership TransitionJuly 28, 2025 | finanznachrichten.deAclaris Therapeutics Announces Leadership TransitionJuly 28, 2025 | globenewswire.comAclaris Therapeutics (NASDAQ:ACRS) Earns Overweight Rating from Piper SandlerJuly 10, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from BrokeragesJuly 7, 2025 | marketbeat.comAclaris Therapeutics Joins Russell 3000 and Russell 2000 IndexesJuly 2, 2025 | msn.comACRS Aclaris Therapeutics, Inc. - Seeking AlphaJuly 1, 2025 | seekingalpha.comAclaris Therapeutics Added to the Russell 2000® and Russell 3000® IndexesJune 30, 2025 | globenewswire.comAclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual ConferenceJune 26, 2025 | finance.yahoo.comAclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual ConferenceJune 26, 2025 | globenewswire.comHC Wainwright Reaffirms "Buy" Rating for Aclaris Therapeutics (NASDAQ:ACRS)June 25, 2025 | marketbeat.comAclaris Therapeutics Inc News (ACRS) - Investing.comJune 24, 2025 | investing.comAclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052June 23, 2025 | msn.comAclaris Therapeutics' (ACRS) "Outperform" Rating Reaffirmed at WedbushJune 23, 2025 | marketbeat.comAclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052June 23, 2025 | globenewswire.comAssenagon Asset Management S.A. Purchases 284,191 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)June 19, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Buy" by BrokeragesJune 12, 2025 | marketbeat.comBank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)June 11, 2025 | marketbeat.comAclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic DermatitisJune 2, 2025 | finance.yahoo.comWhat is Wedbush's Estimate for ACRS Q2 Earnings?May 31, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Lowered by Two Sigma Advisers LPMay 30, 2025 | marketbeat.comMillennium Management LLC Decreases Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)May 30, 2025 | marketbeat.comAclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025May 29, 2025 | msn.comWedbush Initiates Coverage of Aclaris Therapeutics (ACRS) with Outperform RecommendationMay 29, 2025 | msn.comAclaris Therapeutics (NASDAQ:ACRS) Now Covered by WedbushMay 29, 2025 | marketbeat.comAclaris Therapeutics to Participate in Two June Healthcare ConferencesMay 28, 2025 | globenewswire.comStonepine Capital Management LLC Has $1.65 Million Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)May 20, 2025 | marketbeat.comJanus Henderson Group PLC Takes $6.99 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)May 20, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by BrokeragesMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 339,467 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)May 19, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Bought by Cubist Systematic Strategies LLCMay 18, 2025 | marketbeat.comAclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025May 12, 2025 | msn.comAclaris Therapeutics Reports Q1 2025 Results and Pipeline UpdatesMay 11, 2025 | msn.com Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRS Media Mentions By Week ACRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼0.811.03▲Average Medical News Sentiment ACRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼53▲ACRS Articles Average Week Get the Latest News and Ratings for ACRS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aclaris Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BGM Group News Today Oculis News Today Mind Medicine (MindMed) News Today Nurix Therapeutics News Today Tango Therapeutics News Today Ginkgo Bioworks News Today Day One Biopharmaceuticals News Today ProKidney News Today Theravance Biopharma News Today Immatics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access